Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NACDS Fills Top Spot With Former Bush Aide Fuller

This article was originally published in The Tan Sheet

Executive Summary

The National Association of Chain Drug Stores will retain its close leadership ties with the Republican party under President and CEO-elect Craig Fuller.

You may also be interested in...

NACDS Card-Based Consumer Loyalty Program Will Kick Off In Three Chains

The National Association of Chain Drug Stores is launching a card-based consumer loyalty program in September at three chain pharmacies.


Robert Hannan will serve as interim president and CEO following Ronald Ziegler's retirement Feb. 28. Hannan was president and CEO of Thrift Drug for 10 years until the chain was acquired by J.C. Penney and merged with Eckerd in 1997. After serving as Eckerd vice chairman during the transition, Hannan retired in 1998. He was NACDS chairman from 1993 to 1994. Ziegler will retire at the end of February "because of health reasons," NACDS announces Feb. 8. Ziegler previously said he would retire in December 2000 after a successor was named ("The Tan Sheet" Feb. 1, p. 27). However, in a series of meetings with the association board in Miami, "he concluded that it was in his best interest to initiate his retirement sooner than originally planned," NACDS says. The association emphasizes that "Ziegler and the entire board hold one another in the highest regard and in the highest terms of respect"

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts